Open in interactive viewer → charts, metric popovers & call review

Lineage Pays $4.3 Million for a Huntington's Program and Calls It Transformational

A $250 million cell-therapy developer pivots its story away from an OpRegen it can't discuss and toward a striatal transplant it has owned for eight hours — with the stock down 29% in 90 days and no tape confirmation yet
LCTX · Earnings Call · 2026-11-12

Eight Hours of Ownership

Brian Culley opened Lineage's third-quarter call the way he opens every call: with OpRegen, the Roche/Genentech-partnered retinal cell program that has been the company's entire investment case for years. Four paragraphs later, the call changed shape. “Just a few minutes ago, we announced that we had acquired NeuroAirmid Therapeutics, a private biotech company founded on technology licensed from the lab of world-leading Huntington's disease researcher, Dr. Leslie Thompson.” — Brian Culley, Chief Executive Officer · 2026-11-12 The asset is HUNT1, an allogeneic neural progenitor cell therapy injected directly into the striatum of Huntington's disease patients, currently in a Phase Ib/IIa called REGEN4HD run out of UC Irvine. The framing was conspicuous. Culley laid out a "10 key points" list, walked the audience through the science, the economics, the manufacturing fit and the competitive landscape — and then, when Mayank Mamtani asked what a good 12-month readout would look like, reminded everyone how fresh this all is: “It's correct that it's early. We've owned it for 8 hours.” — Brian Culley, Chief Executive Officer · 2026-11-12 That is a fair summary of the risk. Six patients have been dosed across Cohorts A and B, no serious adverse events reported, and the primary endpoint is safety at six weeks. Everything else — the UHDRS functional scores, the neurofilament light chain, the FDG-PET — is exploratory. What is far less ambiguous is that Lineage's narrative vocabulary has rotated. The company's own keyword registry has been dominated for a year by AlloSCOPE, RPE transplant language, the DOSED study and islet cell work. This quarter the biggest movers are all Huntington-adjacent: HUNT1, Huntington, NeuroAirmid, striatum, neurons, precursor, HUNT1 program. That is a genuinely new theme for this company — not a rephrasing of an old one — and it arrived with a companion admission: the pipeline is now three clinical-stage assets, and the newest one is the only one management can speak freely about.

The Price of a Third Clinical Asset

Jill Howe's numbers are the part of the deck that actually holds up to scrutiny.

In the aggregate, our external cash payments on day 1 were approximately $4.3 million, a number we feel not only reflects exceptional value for clinical stage assets, but also fits well within our capability for investment.

Jill Howe, Chief Financial Officer · 2026-11-12
That is $2.4 million cash plus roughly 2.2 million shares, with another tranche due on the first anniversary and all remaining consideration contingent on clinical progress and payable half in stock at Lineage's election. Ongoing clinical cost is under $2 million a year, and the trial itself is majority-funded by a $12 million CIRM grant to UC Irvine that Lineage co-funds up to $3.1 million. Against a stated budget run rate of roughly $30 million a year, this is a rounding error. The deal is small. The word management used for it was "transformational." Both can be true, but only one of them is arithmetic. The balance sheet got the real headline: “As of September 30, 2026, we had $45.2 million in cash, cash equivalents and marketable securities, which we expect will fund planned operations into the second quarter of 2028.” — Jill Howe, Chief Financial Officer · 2026-11-12 That is one quarter earlier than prior guidance — the first time in memory this company has shortened its runway rather than extended it. The last filed balance sheet, for the quarter ended August 3, showed effective net cash of about $27 million, down 10% year over year, so the $45.2 million figure reflects subsequent warrant exercises, not operating cash generation. Operating cash generation is the problem. Total revenue of about $1 million fell 61% year over year from a 2026Q1 peak of $4 million, as deferred Roche collaboration revenue burns off and the Demant research collaboration slows. Research and development ran at roughly five times revenue in the latest quarter. And the reported net income of $4.2 million is an artifact, not a profit — it comes from fair-value remeasurement of the warrant liability in a falling share price. Lineage's income statement now improves when its stock goes down. Which brings up the biggest lever nobody on the call wanted to dwell on: a price-to-revenue multiple above 25x sitting on top of $32 million of warrants struck at $0.91, a three-year term that condenses to 90 days if Roche and Genentech merely disclose intent to run a controlled OpRegen trial. The single largest cash event in Lineage's control belongs to a partner and is triggered by a press release.

What Management Stopped Talking About

The most informative number on the call was not on the call. OpRegen — the lead program, the $615 million of milestones, the double-digit royalty — got roughly two paragraphs and two analyst questions. Culley's closest thing to news was confirming that public FDA records showing several hundred vials of OpRegen shipped to Genentech are accurate, and noting a competitor's Phase Ib slipped to a primary completion date of December 31, 2027. That is a third-hand data point dressed as a catalyst. He knows it. “I can maybe divine from the question that it's frustrating for a lot of people that we don't have the same level of information with respect to the OpRegen program.” — Brian Culley, Chief Executive Officer · 2026-11-12 The analyst corps has been circling this for years. On the August call, Joe Pantginis prefaced one question with “I'm going to ask, I guess, the 47th version of a proxy question regarding OpRegen” — Brian Culley, Chief Executive Officer (CEO) · 2026-08-06, and Culley answered a different one by comparing a regulatory filing to “another tea leaf. But I invite the listeners to consider how many tea leaves start to make you feel that there's some asymmetry in a possible positive outcome here.” — Brian Culley, Chief Executive Officer (CEO) · 2026-08-06 Six months later the tea leaves have not become data. Meanwhile the keywords have quietly decayed. RPE transplant was one of the company's sharpest decliners last quarter; royalty fell off this quarter; the DOSED study is now a declining term despite the third OPC1 patient being scheduled for December 8. Management did not abandon these programs. It abandoned narrating them. That is a tell, and it is the kind of tell that a 10-key-point acquisition presentation is designed to cover.

The Tape Hasn't Voted

As of November 13, the day after the call, LCTX closed 28.5% below its July 10 peak of $1.28 in a single unbroken 90-day downtrend, on a $250 million market cap, against a full-history return of −79.9% and a drawdown of 90.6% from the 2010 high of $9.69. The deal landed into weakness and produced no visible reversal. Nobody has re-rated anything yet. Nor is there a wave to ride. Huntington's disease, neural transplantation and striatal delivery appear nowhere in the market's top-75 themes across the last twelve quarters, which are dominated by AI data centers, tariffs, memory pricing and rate expectations. Among the dozens of companies reporting in the same five-day window, none echoed this theme — the nearest neighbor is a rare-disease congress mention. This is not a company ahead of a broader wave, or riding one. It is a company building its own isolated narrative in a tape that is looking elsewhere. That leaves the honest reading. Lineage bought a third clinical-stage asset for less than the cost of two months of R&D, wrapped a new story around it, and did so without touching its runway by more than a quarter. The genuinely interesting optionality sits further out and lower down the pipeline: islet cell therapy precursors differentiated for the first time in the 5D system, COR1 corneal data expected in Q1 2027, and a Danish Medicines Agency meeting for ReSonance in December. Those are cheap call options on a platform, and they cost shareholders nothing extra today. But the value-creating event that would actually move a $250 million stock is still a Roche disclosure that Lineage cannot make, cannot time, and cannot preview. The company just spent $4.3 million and a share-holder register to change the subject. Whether the subject needed changing is precisely what investors have been asking for 47 versions of the same question.